Human ATP-binding cassette (ABC) transporter ABCG2 (BCRP) is critically involved in multidrug resistance of human cancer. This transporter exhibits broad substrate specificity toward structurally diverse compounds, as do other ABC transporters, such as ABCB1 (P-glycoprotein/MDR1), ABCC1 (MRP1/GS-X pump), and ABCC2 (MRP2/cMOAT). To gain insight into the relationship between the molecular structure of compounds and the ABCG2-mediated transport activity, we have developed a high-speed screening method to analyze the substrate specificity of ABCG2. In addition, we have developed an algorithm that analyzes QSAR to evaluate ABCG2–drug interactions. This chapter presents our strategy of transport mechanism-based molecular design to circumvent multidrug resistance of cancer.
ABC transporter ABCG2 (BCRP) Cancer Protein kinase inhibitor Quantitative structure–activity relationship (QSAR)
This is a preview of subscription content, log in to check access.
Springer Nature is developing a new tool to find and evaluate Protocols. Learn more
Saito H, Hirano H, Nakagawa H et al (2006) A new strategy of high-speed screening and quantitative structure–activity relationship analysis to evaluate human ATP-binding cassette transporter ABCG2-drug interactions. J Pharmacol Exp Ther 317:1114–1124PubMedCrossRefGoogle Scholar
Mitomo H, Kato R, Ito A et al (2003) A functional study on polymorphism of the ATP-binding cassette transporter ABCG2: critical role of arginine-482 in methotrexate transport. Biochem J 373:767–774PubMedCrossRefGoogle Scholar
Ishikawa T, Kasamatsu S, Hagiwara Y et al (2003) Expression and functional characterization of human ABC transporter ABCG2 variants in insect cells. Drug Metab Pharmacokinet 18:194–202PubMedCrossRefGoogle Scholar
Hirano H, Kurata A, Onishi Y et al (2006) High-speed screening and QSAR analysis of human ATP-binding cassette transporter ABCB11 (bile salt export pump) to predict drug-induced intrahepatic cholestasis. Mol Pharm 3:252–265PubMedCrossRefGoogle Scholar
Ishikawa T, Ikegami Y, Sano K et al (2006) Transport mechanism-based drug molecular design: novel camptothecin analogues to circumvent ABCG2-associated drug resistance of human tumor cells. Curr Pharm Design 12:313–325CrossRefGoogle Scholar
Saito H, An R, Hirano H et al (2010) Emerging new technology: QSAR analysis and MO calculation to characterize the interaction of protein kinase inhibitors with human ABC transporter ABCG2 (BCRP). Drug Metab Pharmacokinet 25:72–83PubMedCrossRefGoogle Scholar
Sakurai A, Onishi Y, Hirano H et al (2007) Quantitative SAR analysis and molecular dynamic simulation to functionally validate nonsynonymous polymorphisms of human ABC transporter ABCB1. Biochemistry 46:7678–7693PubMedCrossRefGoogle Scholar